A solution guide for evaluating synthetic health data workflows for testing, development, analytics, privacy review, model validation, and data governance.
Summary
Synthetic health data can support development and testing, but buyers still need clear provenance, privacy review, representativeness checks, and governance.
Workflow checkpoints
Generation purpose and provenance
Synthetic data should have a defined purpose, source context, generation method, and limits on downstream use.
- Document whether data is synthetic, deidentified, transformed, or sampled.
- Track source provenance and generation settings.
- Separate testing use from clinical, billing, or patient-impacting use.
Validation and privacy review
Synthetic data should be evaluated for privacy risk, representativeness, bias, leakage, and suitability for the intended workflow.
- Assess reidentification and leakage risk.
- Validate subgroup representation and missingness patterns.
- Define approval before using synthetic data in model evaluation or demos.
Evaluation criteria
- Generation method, source provenance, privacy review, representativeness, and intended-use boundaries.
- Fit for testing, demos, integration development, analytics, or validation without patient-impacting decisions.
- Governance over retention, access controls, model-training exclusions, audit logs, and vendor support access.
Health data infrastructure
Tools that support health data exchange, normalization, testing, and integration workflows.
Related tools: redox, health-gorilla, particle-health, zus-health
Privacy and compliance infrastructure
Tools that support HIPAA-oriented controls, data handling, and governance workflows.
Related tools: truevault, aptible
Compliance considerations
- Do not assume synthetic data is automatically privacy-safe or clinically representative.
- Review provenance, PHI exposure risk, deidentification method, BAA terms, retention, and access controls.
- Define allowed uses, prohibited uses, model-training exclusions, and approval workflow before sharing data.
Medical and editorial note
This solution guide is for synthetic health data procurement research and is not medical, privacy, deidentification, regulatory, legal, or compliance advice.
Sources and review notes
These links support workflow-level research and do not establish the regulatory status, clinical safety, diagnostic performance, or suitability of any product.
NIST SP 800-188 describes synthetic data as one possible data-sharing model within a broader de-identification and disclosure-governance program. The guidance is written for U.S. government datasets, not as a HIPAA compliance standard, and recommends defining release goals and risks, measurable performance levels, expert governance and re-identification studies. It also cautions that tools which merely mask information may not perform de-identification. HHS provides Safe Harbor and Expert Determination as the two methods for satisfying the HIPAA Privacy Rule's de-identification standard and notes that properly de-identified data retains a very small but nonzero identification risk. Generating synthetic records from PHI is itself processing of PHI and does not automatically make the source, model, intermediate artifacts or outputs de-identified. FDA's Good Machine Learning Practice principles address representative datasets, independence between training and test data, clinically relevant testing, human-AI-team performance and lifecycle monitoring for AI-enabled medical devices; they do not approve synthetic data or require those principles for every operational use. NIST AI RMF is voluntary and cross-sector and supplies governance, measurement and monitoring concepts rather than a synthetic-data certification. These sources do not make synthetic data inherently private, unbiased, realistic, clinically valid or suitable for a downstream decision. Buyers should define whether a dataset is fully synthetic, partially synthetic, simulated from explicit rules, transformed from real records, sampled, masked, tokenized or de-identified; identify the source population and time period, legal and contractual authority, source and generator access to PHI, generation method and version, privacy mechanism and parameters, intended recipients and environment, allowed purpose, prohibited decisions, utility target, retention, release frequency and accountable reviewers. Preserve source-data lineage without exposing source PHI to unauthorized users, generator configuration and randomness controls, code and dependency versions, training and holdout boundaries, filtering and post-processing, disclosure and utility test results, known limitations, approval, release identifier and every downstream copy or derivative. Privacy evaluation should match the threat model and test exact and near duplication, rare records and outliers, memorized text and identifiers, nearest-source similarity, membership and attribute inference, linkage with recipient-held and public data, repeated and overlapping releases, deterministic seeds, prompts and logs, model access, metadata and hidden fields. A low average similarity score or failure of one attack does not establish absence of disclosure risk. Utility and fidelity should be evaluated separately for the intended task across schema and code validity, marginal and joint distributions, correlations, longitudinal and event ordering, missingness, units and ranges, clinical and operational constraints, rare events, subgroup representation, label prevalence, calibration and downstream performance. High overall fidelity can preserve harmful bias or privacy risk, while aggressive protection can erase rare but important patterns. Acceptance testing should include train-on-synthetic and test-on-independent-real comparisons where lawful and appropriate, real-data baselines, negative and edge cases, data and generator shifts, multiple releases, corrupted and incomplete source data, unsupported modalities, and users attempting prohibited clinical, billing or patient-level use. Synthetic data may support software tests, demos, interface development, training exercises and exploratory analytics only when the generated values and relationships are adequate for that bounded purpose; it is not evidence that a production model, clinical workflow, quality measure, claim, safety control or integration works on real patients and systems. Measure privacy-test results and coverage, exact and near duplicates, release and access exceptions, schema and constraint violations, distribution and subgroup divergence, rare-event retention, downstream task error against independent real data, misleading or impossible records, reviewer findings, utility loss, regeneration drift, incidents and staff effort. Report results by use case and release rather than a single quality score. Governance and contracts should require qualified privacy, statistical, clinical, research, security, legal and compliance review; least-privilege source and model access; model-training and reuse restrictions; disclosure review; audit logs; cumulative-release monitoring; version and change control; retention, deletion and revocation; incident response; export and vendor exit. Systems must not label data synthetic or de-identified without documented method and validation, expose source memorization or linkage keys, use production PHI for generation without authority, fabricate synthetic outputs as real clinical evidence, hide underrepresented groups or failed tests, or permit patient-impacting, clinical, billing, regulatory or safety decisions based only on synthetic validation.
